Immunotoxin-mediated targeting of claudin-4 inhibits the proliferation of cancer cells

Hashimi,S.  M.; Yu,S.; Alqurashi,N.; Ipe,D. S.; Wei,M.  Q.

doi:10.3892/ijo.2013.1881

Immunotoxin-mediated targeting of claudin-4 inhibits the proliferation of cancer cells

Authors:
- S. M. Hashimi
- S. Yu
- N. Alqurashi
- D. S. Ipe
- M. Q. Wei
View Affiliations

Affiliations: Division of Molecular and Gene Therapies, Griffith Health Institute and School of Medical Science, Griffith University, Gold Coast, Queensland 4215, Australia
Published online on: April 4, 2013 https://doi.org/10.3892/ijo.2013.1881
Pages: 1911-1918

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Immunotoxins are engineered chimeric proteins that consist of a fragment of a toxin fused to a modified antibody or growth factor capable of targeting specific cells. Furthermore, these proteins can be targeted to receptors that are commonly overexpressed on cancer cells. The majority of immunotoxins function by binding to cells, translocating into the cytosol and inhibiting protein synthesis. In this study, the expression of claudin‑4 (CLDN4) in various cancer cells was analysed as a potential target for immunotoxins. To target CLDN4-expressing cancer cells, the c-terminal CLDN4‑binding domain of Clostridium perfringens enterotoxin (CPE) was fused to the Pseudomonas aeruginosa exotoxin A (ETA) domain to create an immunotoxin (CPE‑ETA'). Subsequently, the capacity of such an immunotoxin in suppressing the proliferation of CLDN4-positive cancer cells was investigated. We report that head and neck squamous carcinoma cells (HN5) have an elevated CLDN4 expression compared to the other cell lines tested. Our findings further demonstrate that CPE‑ETA' is highly potent against MCF-7 breast [50% inhibitory concentration (IC50) 9.8 ng/ml] and HN5 head/neck (IC50 8.8 ng/ml) cancer cell lines, while it has no cytotoxic effects on HeLa cells (CLDN4‑negative). The immunotoxin was subsequently expressed in the tumour colonising oncolytic strain, Clostridium ghonii. Most importantly, the strictly anaerobic Clostridium ghonii was able to overexpress and secrete a functional CPE‑ETA' fusion protein. Our findings open the possibility of the targeted delivery of the immunotoxin locally to tumour sites at a high concentration using strictly anaerobic Clostridium ghonii for the treatment of CLDN4-positive cancer cells.

View Figures

View References

1	Lucas R and Keisari Y: Innovative cancer treatments that augment radiotherapy or chemo-therapy by the use of immunotherapy or gene therapy. Recent Pat Anticancer Drug Discov. 1:201–208. 2006. View Article : Google Scholar : PubMed/NCBI
2	Krause G, Winkler L, Mueller SL, Haseloff RF, Piontek J and Blasig IE: Structure and function of claudins. Biochim Biophys Acta. 1778:631–645. 2008. View Article : Google Scholar : PubMed/NCBI
3	Lal-Nag M and Morin PJ: The claudins. Genome Biol. 10:2352009. View Article : Google Scholar
4	Saeki R, Kondoh M, Kakutani H, et al: A novel tumor-targeted therapy using a claudin-4-targeting molecule. Mol Pharmacol. 76:918–926. 2009. View Article : Google Scholar : PubMed/NCBI
5	Morin PJ: Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res. 65:9603–9606. 2005. View Article : Google Scholar : PubMed/NCBI
6	Suzuki M, Kato-Nakano M, Kawamoto S, et al: Therapeutic antitumor efficacy of monoclonal antibody against claudin-4 for pancreatic and ovarian cancers. Cancer Sci. 100:1623–1630. 2009. View Article : Google Scholar : PubMed/NCBI
7	Ling J, Liao H, Clark R, Wong MS and Lo DD: Structural constraints for the binding of short peptides to claudin-4 revealed by surface plasmon resonance. J Biol Chem. 283:30585–30595. 2008. View Article : Google Scholar : PubMed/NCBI
8	Michl P, Buchholz M, Rolke M, et al: Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology. 121:678–684. 2001. View Article : Google Scholar : PubMed/NCBI
9	Pier GB, Boyer D, Preston M, et al: Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains. J Immunol. 173:5671–5678. 2004.PubMed/NCBI
10	Phelan MC: Basic techniques in mammalian cell tissue culture. Curr Protoc Cell Biol. Chapter 1: Unit 1 1. 2007. View Article : Google Scholar
11	Kurien BT and Scofield RH: Introduction to protein blotting. Methods Mol Biol. 536:9–22. 2009. View Article : Google Scholar : PubMed/NCBI
12	Yao Q, Cao S, Li C, et al: Turn a diarrhoea toxin into a receptor-mediated therapy for a plethora of CLDN-4-overexpressing cancers. Biochem Biophys Res Commun. 398:413–419. 2010. View Article : Google Scholar : PubMed/NCBI
13	Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
14	Dong H, Zhang Y, Dai Z and Li Y: Engineering Clostridium strain to accept unmethylated DNA. PLoS One. 5:e90382010.
15	Barbé S, Van Mellaert L and Anné J: The use of clostridial spores for cancer treatment. J Appl Microbiol. 101:571–578. 2006.
16	Litkouhi B, Kwong J, Lo CM, et al: Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin. Neoplasia. 9:304–314. 2007. View Article : Google Scholar
17	Lanigan F, McKiernan E, Brennan DJ, et al: Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer. Int J Cancer. 124:2088–2097. 2009. View Article : Google Scholar : PubMed/NCBI
18	Ueda J, Semba S, Chiba H, et al: Heterogeneous expression of claudin-4 in human colorectal cancer: decreased claudin-4 expression at the invasive front correlates cancer invasion and metastasis. Pathobiology. 74:32–41. 2007. View Article : Google Scholar : PubMed/NCBI
19	Landers KA, Samaratunga H, Teng L, et al: Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer. Br J Cancer. 99:491–501. 2008. View Article : Google Scholar : PubMed/NCBI
20	Kominsky SL, Vali M, Korz D, et al: Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. Am J Pathol. 164:1627–1633. 2004. View Article : Google Scholar
21	Barth S, Huhn M, Matthey B, et al: Recombinant anti-CD25 immunotoxin RFT5(SCFV)-ETA’ demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice. Int J Cancer. 86:718–724. 2000.
22	Wei MQ, Mengesha A, Good D and Anné J: Bacterial targeted tumour therapy-dawn of a new era. Cancer Lett. 259:16–27. 2008. View Article : Google Scholar : PubMed/NCBI
23	Frederick BA, Helfrich BA, Coldren CD, et al: Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther. 6:1683–1691. 2007. View Article : Google Scholar : PubMed/NCBI
24	Rangel LB, Agarwal R, D’Souza T, et al: Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res. 9:2567–2575. 2003.PubMed/NCBI
25	Li J, Sherman-Baust CA, Tsai-Turton M, Bristow RE, Roden RB and Morin PJ: Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. BMC Cancer. 9:2442009. View Article : Google Scholar : PubMed/NCBI
26	Meertens L, Bertaux C, Cukierman L, et al: The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus. J Virol. 82:3555–3560. 2008. View Article : Google Scholar : PubMed/NCBI
27	Gourin CG and Podolsky RH: Racial disparities in patients with head and neck squamous cell carcinoma. Laryngoscope. 116:1093–1106. 2006. View Article : Google Scholar : PubMed/NCBI
28	Al-Sarraf M: Treatment of locally advanced head and neck cancer: historical and critical review. Cancer Control. 9:387–399. 2002.PubMed/NCBI
29	Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
30	Wei MQ, Ipe D, Cao S and Hashimi S: Genetic Modification to Improve the Therapeutic Potential of Oncolytic Clostridia. Advances in Genetics Research. Urbano KV: 8. Nova Publishers; Hauppauge, NY: pp. 65–82. 2011
31	Cao S, Cripps A and Wei MQ: New strategies for cancer gene therapy: progress and opportunities. Clin Exp Pharmacol Physiol. 37:108–114. 2010. View Article : Google Scholar : PubMed/NCBI
32	Theys J, Pennington O, Dubois L, et al: Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo. Br J Cancer. 95:1212–1219. 2006.
33	Groot AJ, Mengesha A, van der Wall E, van Diest PJ, Theys J and Vooijs M: Functional antibodies produced by oncolytic clostridia. Biochem Biophys Res Commun. 364:985–989. 2007. View Article : Google Scholar : PubMed/NCBI